Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566.HK)

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. operates as a biopharmaceutical company. The company is headquartered in Hangzhou, Zhejiang and currently employs 1,629 full-time employees. The company went IPO on 2024-11-28. The firm focuses on orthopedics, metabolic diseases, oncology and blood treatment. The firm's orthopedic products include Guyoudao bone repair materials. The firm's oncology products include Jilifen, Jijufen, Jiouting, Jifuwei, and Jitansu. The firm's blood products include Jipailin and Yinuojia. The firm's products are mainly used to treat diseases such as diabetes, multiple myeloma, thrombocytopenia, and neutropenia. The firm mainly operates its businesses in the domestic and overseas markets.